COMPASS PATHWAYS PLC Income (Loss) from Continuing Operations before Income Taxes, Domestic
COMPASS PATHWAYS PLC (CMPS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$293.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-24
- COMPASS PATHWAYS PLC income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$293.93M.
- COMPASS PATHWAYS PLC income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$156.71M.
- COMPASS PATHWAYS PLC income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$120.32M.
- COMPASS PATHWAYS PLC income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$92.84M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$293.93M 10-K · filed 2026-03-24 |
| 2024-12-31 | -$156.71M 10-K · filed 2026-03-24 |
| 2023-12-31 | -$120.32M 10-K · filed 2025-02-27 |
| 2022-12-31 | -$92.84M 10-K · filed 2024-02-29 |
| 2021-12-31 | -$72.40M 10-K · filed 2024-02-29 |
| 2020-12-31 | -$60.52M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$19.62M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |